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pig heart ATTs utilize tyrosine, phenylalanine, and tryptophan [1] and 
the rat liver AA T will utilize either a-ketoglutarate or oxalacetate as 
cosubstrates with tyrosine [2]. Their strongest evidence is the antibody 
data, since added oxalacetate might be exerting its effect through an 
initial transamination with endogenous glutamate to yield a-ketoglu-
tarate. 
The question raised by Thorpe and Goldsmith is whether the con-
version of tyrosine to p-hydroxyphenylpyruvate which we observed in 
the supernatant fraction of mouse skin from newborns is the result of 
the action of cytoplasmic tyrosine aminotransferase, or that of mito-
chondrial aspartic aminotransferase. We did not have available anti-rat 
liver TAT, and thus cannot give a definitive answer. We did show that 
the TAT activity in newborn mouse skin was inhibited by 2 compounds 
(p-hydroxy-phenylacetic acid and 3,4-dihydroxyphenylacetic acid) 
which also inhibit cytoplasmic TAT of rat liver to the same extent. It 
appears that the mitochondrial TAT activity has not been studied with 
these inhibitors. Although we measured the activity in a high speed 
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supernatant, it is still possible that the mitochondrial enzyme was 
extracted into the supernatant. The question thus remains open as to 
whether the activity measured in mouse skin belongs to tyrosine 
aminotransferase or to another aminotransferase of broad specificity. 
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Correction 
In the February 1980 issue of the Journal (vol. 74), Figures 1 and 2 (page 75) in the article "Epidermal 
Cyclic AMP Is Not Decreased in Psoriasis Lesions" by Adachi et al should have appeared on page 82 
instead of on page 75. Figures 1 and 2 (page 82) in the article "Increased Granulocyte Adherence in 
Psoriasis and Psoriatic Arthritis" by Sedgwick, Bergstresser, and Hurd should have appeared on page 75 
instead of on page 82. 
The illustrations and their correct legends appear here. 
Increased Granulocyte Aherence in Psoriasis and Psoriatic Arthritis 
Julie B. Sedgwick, M.S., Paul R. Bergstresser, M.D., and Eric R. Hurd, M.D . 
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FIG 1. Percent PMN adherence for control and psoriasis groups. 
Horizontal bars represent the man for each group. n.s. = not statisti-
cally significant. 
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FIG 2. Percent PMN adherence for normal controls, psoriatic arthl'itis 
patients and psoriasis patients according to extent of disease. Horizon-
tal bars represent the mean for each group. 
